1. A Post Hoc Sensitivity Analysis of Survival Probabilities in a Multinational Phase III Trial of Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia 
Xavier G. Thomas, Christopher Arthur, Jacques Delaunay, Mark Jones, Erhan Berrak, Hagop M. Kantarjian 
Clinical Lymphoma, Myeloma and Leukemia 
Volume 14, Issue 1, Pages (February 2014)
DOI: /j.clml
Copyright © 2014 Elsevier Inc. Terms and Conditions

2. Figure 1
Overall Survival (95% CI) for the Intent-to-Treat Population for Decitabine and Treatment Choice Arms at 3, 6, 12, 18, and 24 Months for the 2010 Mature Data Set. The Hazard Ratio (HR) and P Value for the Difference Between the 2 Arms are Shown at Each Time Point, Using Cox Proportional Hazard Model Stratified According to age, Cytogenetic Risk, and Eastern Cooperative Oncology Group (ECOG) Performance Status. A Hazard Ratio < 1 Favors Decitabine
Clinical Lymphoma, Myeloma and Leukemia  , 68-72DOI: ( /j.clml )
Copyright © 2014 Elsevier Inc. Terms and Conditions